Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings No

被引：9
作者：
Strauss, Martin H. [1 ]
Hall, Alistair [1 ]
机构：
[1] Univ Leeds, C NET Res Grp, LIGHT, Fac Med, Leeds LS2 9JT, W Yorkshire, England
来源：
STROKE | 2009年 / 40卷 / 09期
关键词：
prevention; receptors; ARB; stroke; renin angiotensin system; CONVERTING ENZYME-INHIBITORS; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; HIGH-RISK; TELMISARTAN; MORBIDITY; MORTALITY; TRIAL;
D O I：
10.1161/STROKEAHA.109.559062
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：3161 / 3162
页数：2
相关论文
共 10 条
[1]  
[Anonymous], 2007, J HYPERTENS
[2]   Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II [J].
Boutitie, Florent ;
Oprisiu, Roxana ;
Achard, Jean Michel ;
Mazouz, Hakim ;
Wang, Jiguang ;
Messerli, Franz H. ;
Gueyffier, Francois ;
Fournier, Albert .
JOURNAL OF HYPERTENSION, 2007, 25 (08) :1543-1553
[3]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[4]   Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention -: Principal results of a prospective randomized controlled study (MOSES) [J].
Schrader, J ;
Lüders, S ;
Kulschewski, A ;
Hammersen, F ;
Plate, K ;
Berger, J ;
Zidek, W ;
Dominiak, P ;
Diener, HC .
STROKE, 2005, 36 (06) :1218-1224
[5]   Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradox [J].
Strauss, Martin H. ;
Hall, Alistair S. .
CIRCULATION, 2006, 114 (08) :838-854
[6]   Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention [J].
Verdecchia, P ;
Reboldi, G ;
Angeli, F ;
Gattobigio, R ;
Bentivoglio, M ;
Thijs, L ;
Staessen, JA ;
Porcellati, C .
HYPERTENSION, 2005, 46 (02) :386-392
[7]   Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers - A quantitative overview [J].
Wang, Ji-Guang ;
Li, Yan ;
Franklin, Stanley S. ;
Safar, Michel .
HYPERTENSION, 2007, 50 (01) :181-188
[8]   Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial [J].
Yusuf, S. ;
Teo, K. ;
Anderson, C. ;
Pogue, J. ;
Dyal, L. ;
Copland, I. ;
Schumacher, H. ;
Dagenais, G. ;
Sleight, P. .
LANCET, 2008, 372 (9644) :1174-1183
[9]   Telmisartan to prevent recurrent stroke and cardiovascular events [J].
Yusuf, Salim ;
Diener, Hans-Christoph ;
Sacco, Ralph L. ;
Cotton, Daniel ;
Ounpuu, Stephanie ;
Lawton, William A. ;
Palesch, Yuko ;
Martin, Renee H. ;
Albers, Gregory W. ;
Bath, Philip ;
Bornstein, Natan ;
Chan, Bernard P. L. ;
Chen, Sien-Tsong ;
Cunha, Luis ;
Dahlof, Bjorn ;
De Keyser, Jacques ;
Donnan, Geoffrey A. ;
Estol, Conrado ;
Gorelick, Philip ;
Gu, Vivian ;
Hermansson, Karin ;
Hilbrich, Lutz ;
Kaste, Markku ;
Lu, Chuanzhen ;
Machnig, Thomas ;
Pais, Prem ;
Roberts, Robin ;
Skvortsova, Veronika ;
Teal, Philip ;
Toni, Danilo ;
VanderMaelen, Cam ;
Voigt, Thor ;
Weber, Michael ;
Yoon, Byung-Woo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (12) :1225-1237
[10]   Telmisartan, ramipril, or both in patients at high risk for vascular events [J].
Yusuf, Salim ;
Teo, Koon K. ;
Pogue, Janice ;
Dyal, Leanne ;
Copland, Ingrid ;
Schumacher, Helmut ;
Ingelheim, Boehringer ;
Dagenais, Gilles ;
Sleight, Peter ;
Anderson, Craig .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15) :1547-1559
1